Licensing Agreements

Solidago concludes G-CSF licensing, technology transfer deal with Bioclones

Published in Health Business Week, December 22nd, 2006

The South African biotech industry took another significant leap onto the world stage with the announcement that Solidago, a Swiss-based company that develops and licenses strains of micro-organisms and cell lines, has concluded a G-CSF licensing and technology transfer agreement with local company Bioclones (Pty), Ltd.

Bioclones is owned 49.9% by African Biotechnology Medical Innovation Investments Limited (ABMI) a wholly owned subsidiary of JSE-listed Sekunjalo Investments Limited.

The conclusion of this agreement was made possible by a $5.3 million investment by BioPAD a biotechnology Regional Innovation Centre established by the Department of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2006-12-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry